• Cynata receives firm commitments for $1.5m institutional placement at $0.25 per share
• Placement to strengthen cash runway ahead of Phase 3 osteoarthritis and Phase 2 acute GvHD trial results
• Funds to support commercial partnering discussions and regulatory engagement

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has received firm commitments for a $1.5 million institutional placement. The placement will see the issue of 6 million new shares at $0.25 per share, representing a discount to the company's recent trading prices. The funds will be used to pursue potential commercial partnership transactions following the release of results from Cynata's Phase 3 osteoarthritis and Phase 2 acute graft-versus-host disease (GvHD) clinical trials, which are expected in May and June 2026 respectively. The placement will also support the company's general working capital and costs. Cynata's CEO, Dr Kilian Kelly, stated that the strategically sized placement will minimise dilution while strengthening the company's cash runway as it approaches this pivotal period, allowing it to progress commercial and regulatory activities without losing momentum.

Cynata is planning for success in its upcoming Phase 3 osteoarthritis and Phase 2 acute GvHD trial readouts, and the placement will now better position the company to progress commercial partnering discussions and regulatory engagement.